Vasogen's Celacade trial results to be presented at medical conference

By E. Janene Geiss

Philadelphia, Feb. 1 - Vasogen Inc. announced Wednesday that the pivotal phase 3 trial in peripheral arterial disease has been accepted for presentation at a session of the 55th Annual Scientific Session of the American College of Cardiology.

The meeting, which is being held in Atlanta from March 11 to March 14, attracts about 20,000 cardiovascular professionals from the United States, Canada and the world, according to a company news release.

The initial results of the trial of the company's Celacade technology in peripheral arterial disease will be presented by Dr. Jeffrey Olin on March 12.

Results from the trial will be released at the time of the presentation, officials said.

"The opportunity to present the Simpadico trial results at a late-breaking clinical trial session of the American College of Cardiology recognizes both the quality of this pivotal study and the growing need for new approaches to treat patients with peripheral arterial disease," said Jay H. Kleiman, chief medical officer and head of cardiovascular development of Vasogen, in the release.

The American College of Cardiology selects presentations for late-breaking clinical trial sessions based on the potential of the study to affect clinical practice, the impact and novelty of the research, the rigor of the design/methods, the major clinical endpoints and the quality of the statistical plan.

Vasogen's trial was designed to further investigate the use of its Celacade technology to improve intermittent claudication, a debilitating symptom associated with peripheral arterial diseases.

The study is a double-blind, placebo-controlled trial that enrolled 550 patients at 50 sites in the United States and Canada.

Vasogen is a Toronto biotechnology company focused on the research and commercial development of technologies targeting the chronic inflammation underlying cardiovascular and neurological disease. The company is in the final stages of completing two pivotal phase 3 programs targeting large cardiovascular markets.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.